Pichia Patents (Class 435/254.23)
  • Patent number: 10105384
    Abstract: The present invention concerns a TCTP antagonist, in particular a nucleic acid targeting an m RNA encoding Translationally-Controlled Tumor Protein (TCTP), wherein said nucleic acid is capable of reducing the amount of TCTP in cells, for use in the treatment or prevention of hormone-independent cancer or chemo-resistant cancer, such as an androgen-independent prostate cancer.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: October 23, 2018
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE LA MEDITERRANEE AIX-MARSEILLE II
    Inventors: Palma Rocchi, Virginie Baylot, Julie Acunzo, Claudia Andrieu, Maria Katsogiannou
  • Patent number: 9873746
    Abstract: Methods are provided for the synthesis and secretion of recombinant proteins preferably large mammalian proteins or hetero-multimeric proteins at high levels and for prolonged time in polyploid, preferably diploid yeast. These methods use various mating competent yeast, including Pichia. In a preferred embodiment, a first expression vector is transformed into a first haploid cell; and a second expression vector is transformed into a second haploid cell. The transformed haploid cells, each individually synthesizing a non-identical polypeptide, are identified and then genetically crossed or fused. The resulting diploid strains are utilized to produce and secrete fully assembled and biologically functional hetero-multimeric protein.
    Type: Grant
    Filed: March 24, 2011
    Date of Patent: January 23, 2018
    Assignees: KECK GRADUATE INSTITUTE, ALDERBIO HOLDINGS LLC
    Inventors: James M. Cregg, John Latham, Mark Litton, Randall Schatzman, Ilya Tolstrorukov
  • Patent number: 9796971
    Abstract: A method using yeast as a host for production of human ER chaperone proteins, using endogenous signal peptides of intracellular human proteins that are recognized and correctly processed in the yeast cells to subsequently lead to the secretion of the human proteins. The resultant proteins possessed native amino acid sequence and were biologically active. Moreover, secretion allowed simple one-step purification of native recombinant human proteins with high yields.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: October 24, 2017
    Assignee: UAB BALTYMAS
    Inventors: Evaldas Ciplys, Rimantas Slibinskas, Kestutis Sasnauskas, Marek Michalak, Leslie Ina Gold
  • Patent number: 9359628
    Abstract: The present invention provides genetically engineered strains of Pichia capable of producing proteins with reduced glycosylation. In particular, the genetically engineered strains of the present invention are capable of expressing either or both of an ?-1,2-mannosidase and glucosidase II. The genetically engineered strains of the present invention can be further modified such that the OCH1 gene is disrupted. Methods of producing glycoproteins with reduced glycosylation using such genetically engineered stains of Pichia are also provided.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: June 7, 2016
    Assignees: VIB, VZW, Research Corporation Technologies, Inc., Universiteit Gent
    Inventors: Roland Contreras, Nico L.M. Callewaert, Steven C.J. Geysens
  • Publication number: 20150150152
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel ecdysone receptor/chimeric retinoid X receptor-based inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large-scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
    Type: Application
    Filed: November 24, 2014
    Publication date: May 28, 2015
    Inventors: Marianna Zinovievna KAPITSKAYA, Subba Reddy Palli
  • Publication number: 20150148246
    Abstract: The present invention provides, in part, an antibody display system that simultaneously uses a secretion and a display mode. Embodiments of the invention provide a system in which a bait complexed with a monovalent antibody fragment can be captured prior to secretion in a host cell by virtue of surface displaying an antibody light chain and utilizing the covalent interaction of this light chain with the heavy chain of an antibody molecule that is co-expressed in the same host. Polypeptides, polynucleotides and host cells useful for making the antibody display system are also provided along with methods of using the system for identifying antibodies that bind specifically to an antigen of interest.
    Type: Application
    Filed: May 6, 2013
    Publication date: May 28, 2015
    Inventors: Hussam Hisham Shaheen, Donxing Zha
  • Publication number: 20150139985
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Application
    Filed: October 8, 2014
    Publication date: May 21, 2015
    Inventors: JOHN DESJARLAIS, SEUNG Y. CHU, HOLLY M. HORTON, MATTHEW J. BERNETT
  • Publication number: 20150140626
    Abstract: Provided is a genetically engineered yeast cell with lactate production capacity, including an enzyme that catalyzes conversion of acetaldehyde to acetyl-CoA and an enzyme that catalyzes conversion of pyruvate to lactate, which activities are increased compared to a parent cell of the yeast cell, as well as a method of producing the genetically engineered yeast cell and method of producing lactate using the genetically engineered yeast cell.
    Type: Application
    Filed: November 14, 2014
    Publication date: May 21, 2015
    Inventors: Jiyoon SONG, Changduk KANG, Joonsong PARK, Sungsoo KIM, Youngkyoung PARK, Sunghaeng LEE, Soyoung LEE, Juyoung LEE, Kwangmyung CHO, Wooyong LEE
  • Publication number: 20150140588
    Abstract: The present invention relates to variants with improved activity in an amide-bond reaction. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Application
    Filed: July 3, 2012
    Publication date: May 21, 2015
    Applicant: Novozymes A/S
    Inventors: Werner Besenmatter, Allan Svendsen
  • Publication number: 20150140631
    Abstract: Described is a method for generating conjugated dienes through a biological process. More specifically, the application describes a method for producing conjugated dienes (for example butadiene, isoprene or dimethylbutadiene) from light alkenols via enzymatic dehydration, in particular by making use of an alkenol dehydratase.
    Type: Application
    Filed: January 28, 2015
    Publication date: May 21, 2015
    Inventor: Philippe Marliere
  • Publication number: 20150140625
    Abstract: A genetically engineered yeast cell capable of producing lactate having increased TPI activity, a method of preparing the yeast cell, and a method of producing lactate by using the yeast cell.
    Type: Application
    Filed: November 13, 2014
    Publication date: May 21, 2015
    Inventors: Juyoung Lee, Changduk Kang, Soyoung Lee, Youngkyoung Park, Jiyoon Song, Seunghyun Lee, Kwangmyung Cho
  • Publication number: 20150140001
    Abstract: Provided is an antibody specifically binding to the CTLD (C-type lectin like domain) of clecl4a (C-type lectin domain family 14, member A), a method for preparing the antibody, a composition for suppressing angiogenesis comprising the antibody, a method for suppressing angiogenesis by administering the antibody or the composition, a composition for preventing or treating cancer comprising the antibody, a method for treating cancer by administering the antibody or the composition, a composition for diagnosing cancer comprising the antibody, a kit for diagnosing cancer comprising the composition, a method for diagnosing cancer using the composition, a composition for suppressing angiogenesis comprising a material for inhibiting expression of clecl4a, a kit for angiogenesis comprising the composition, a method for suppressing angiogenesis or treating cancer using the composition, and the use of the CTLD of clecl4a as an epitope for an antibody suppressive of angiogenesis.
    Type: Application
    Filed: June 14, 2013
    Publication date: May 21, 2015
    Applicant: SCRIPPS KOREA ANTIBODY INSTITUTE
    Inventors: Suk Mook Lee, Min kyoung Ki, Mee Hyun Jeoung, Jong Rip Choi
  • Publication number: 20150140638
    Abstract: The present invention relates to isolated polypeptides having endoglucanase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Application
    Filed: February 2, 2015
    Publication date: May 21, 2015
    Inventor: Nikolaj Spodsberg
  • Publication number: 20150132822
    Abstract: The present invention relates to isolated polypeptides having xylanase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Application
    Filed: January 26, 2015
    Publication date: May 14, 2015
    Inventors: Alfredo Lopez de Leon, Michael Rey
  • Publication number: 20150133379
    Abstract: The present invention relates to a fusion protein comprising a skin-penetrating peptide, a polynucleotide encoding the fusion protein, an expression vector comprising the polynucleotide, a transformant comprising the expression vector, a method for preparing the fusion protein, a cosmetic composition for improving skin conditions, which comprises the fusion protein, and a pharmaceutical composition for external skin use, which comprises the fusion protein. The fusion protein of the invention comprises a skin-penetrating peptide bound to a physiologically active protein. The fusion protein significantly enhances the skin penetration and skin retention of the physiologically active protein while maintaining or enhancing the ability of the physiologically active protein to synthesize a material showing physiologically active effects. Thus, it can be widely used as an active ingredient in functional cosmetic compositions and pharmaceutical compositions for external skin use.
    Type: Application
    Filed: April 30, 2014
    Publication date: May 14, 2015
    Inventors: Seol Hoon Lee, Sang Hwa Lee, Nae Gyu Kang, Eu Gene Hur
  • Publication number: 20150132824
    Abstract: The present invention relates to isolated polypeptides having xanthan degrading activity, catalytic domains and polynucleotides encoding the polypeptides and catalytic domains. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides and catalytic domains.
    Type: Application
    Filed: May 7, 2013
    Publication date: May 14, 2015
    Inventors: Dorotea Raventos Segura, Peter Fischer Halin, Anders Viksoe-Nielsen, Lars Anderson, Martin Simon Borchert, Leigh Murphy, Astrid Boisen, Lorena G. Palmén, Kenneth Jensen, Carsten Sjoeholm, Tine Hoff, Charlotte Blom
  • Publication number: 20150125458
    Abstract: The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 7, 2015
    Inventors: Ken Boakye, Alfred Del Vecchio, John Kehoe, Eilyn Lacy, Lynne Murray, Mary Ryan, Sandra Santulli-Marotto, John Wheeler, Brian Whitaker, Alexey Teplyakov
  • Publication number: 20150125893
    Abstract: The invention provides fusion proteins comprising at least one fluorescent protein that is linked to at least one transporter protein that changes three-dimensional conformation upon specifically transporting its substrate. The transporter protein may be a nitrate transporter, a peptide transporter, or a hormone transporter. The invention provides fusion proteins comprising at least one fluorescent protein that is linked to at least one mechanosensitive ion channel protein. The invention also provides for methods of using the fusion proteins of the present invention and nucleic acids encoding the fusion proteins.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 7, 2015
    Inventors: Wolf B. Frommer, Cheng-Hsun Ho
  • Publication number: 20150125902
    Abstract: Provided are isolated polypeptides having glucoamylase activity, catalytic domains, and polynucleotides encoding the polypeptides, catalytic domains. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains.
    Type: Application
    Filed: August 24, 2012
    Publication date: May 7, 2015
    Applicant: Novozymes A/S
    Inventors: Tianqi Sun, Ming Li
  • Publication number: 20150125385
    Abstract: The invention relates to variants of an antibody or antigen-binding fragment that binds specifically to an endosialin tumor endothelial marker 1 (TEM1), and prophylactic, diagnostic, and therapeutic methods using the same.
    Type: Application
    Filed: March 15, 2013
    Publication date: May 7, 2015
    Inventors: George Coukos, Chunsheng Li
  • Publication number: 20150126713
    Abstract: [Problem] An object of the present invention is to provide an anti-human IL-23R antibody having excellent activity and/or cross-reactivity compared to conventional IL-23R antibodies, and means for using the antibody to prevent or treat various diseases such as ophthalmic disease, inflammatory bowel disease, or psoriasis in which human IL-23R is involved in pathogenesis. [Means for Solution] An anti-human IL-23R antibody comprising a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:10 or 14 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:6 or 18.
    Type: Application
    Filed: February 27, 2013
    Publication date: May 7, 2015
    Applicant: Astellas Pharma Inc.
    Inventors: Atsuo Yonezawa, Makoto Ohori, Takanori Sasaki, Hiromu Sato, Katsunari Taguchi
  • Publication number: 20150118721
    Abstract: The invention relates to novel enzymes that provide acetylated sphingoid bases.
    Type: Application
    Filed: March 13, 2013
    Publication date: April 30, 2015
    Applicant: EVONIK INDUSTRIES AG
    Inventors: Steffen Schaffer, Mike Farwick, Heiko Andrea, Tim Koehler, Daniel Wolff, Frank ter Veld, Ansgar Poetsch, Eckhard Boles, Christoph Schorsch
  • Publication number: 20150118260
    Abstract: This invention relates to recombinant CTLA-4 proteins, e.g., soluble CTLA-4 or CTLA-4 fusion toxins, and methods for making and using them.
    Type: Application
    Filed: February 28, 2013
    Publication date: April 30, 2015
    Inventors: Zhirui Wang, David H. Sachs, Christene A. Huang
  • Publication number: 20150118184
    Abstract: A monoclonal antibody recognizing the extracellular region of LAMP5 was produced. The produced antibody demonstrated antibody-dependent cell-mediated cytotoxic activity, and/or cell growth inhibitory activity in the presence of a toxin-labeled secondary antibody, against a multiple myeloma cell line.
    Type: Application
    Filed: March 29, 2013
    Publication date: April 30, 2015
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventor: Shigeto Kawai
  • Publication number: 20150118725
    Abstract: Described is a method for generating isoprenol through a biological process. More specifically, described is a method for producing isoprenol from mevalonate.
    Type: Application
    Filed: April 4, 2013
    Publication date: April 30, 2015
    Inventors: Marc Delcourt, Maria Anissimova, Philippe Marliere
  • Publication number: 20150111222
    Abstract: The present disclosure provides, inter alia, genetically encoded recombinant peptide biosensors comprising analyte-binding framework portions and signaling portions, wherein the signaling portions are present within the framework portions at sites or amino acid positions that undergo a conformational change upon interaction of the framework portion with an analyte.
    Type: Application
    Filed: August 8, 2012
    Publication date: April 23, 2015
    Applicant: HOWARD hUGHES MEDICAL INSTITUTE
    Inventors: Jonathan Marvin, Loren Looger, Richard T. Lee, Eric Schreiter
  • Publication number: 20150110792
    Abstract: Antibodies and antibody fragments that bind to human TIM-1 on the BED face of the protein are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to inhibit or reduce TIM-1 binding to phosphatidylserine, inhibit or reduce TIM-1 binding to dendritic cells, and treat or prevent immunological disorders such as inflammatory and autoimmune conditions.
    Type: Application
    Filed: November 16, 2012
    Publication date: April 23, 2015
    Inventors: Veronique Bailly, Ellen Garber, Paul D. Rennert, Nicholas Joseph Lennemann, Wendy Jean Maury, Sven Henrik Moller-Tank
  • Publication number: 20150111262
    Abstract: This document describes biochemical pathways for producing glutaric acid, 5-aminopentanoic acid, 5-hydroxypentanoic acid, cadaverine or 1,5-pentanediol by forming one or two terminal functional groups, comprised of carboxyl, amine or hydroxyl group, in a C5 backbone substrate such as D-proline.
    Type: Application
    Filed: August 27, 2014
    Publication date: April 23, 2015
    Inventors: Adriana Leonora Botes, Alex Van Eck Conradie
  • Publication number: 20150110765
    Abstract: The present invention relates to isolated polypeptides having alpha-glucuronidase activity, catalytic domains and polynucleotides encoding the polypeptides, catalytic domains. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides or catalytic domains.
    Type: Application
    Filed: April 22, 2013
    Publication date: April 23, 2015
    Inventors: Johan Börjesson, Anders Vikø-Nielsen, Nikolaj Spodsberg, Kristian Krogh
  • Publication number: 20150111817
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: October 16, 2014
    Publication date: April 23, 2015
    Inventors: Ditte RIBER, Jakob Lind TOLBORG, Dieter Wolfgang HAMPRECHT
  • Patent number: 9012179
    Abstract: The present invention relates to a method for mass-producing an antifreeze protein derived from a polar yeast, and more particularly, to a method for mass-producing an antifreeze protein derived from Leucosporidium sp., which is the polar yeast, for synthesizing a recombinant polynucleotide by optimizing and altering a gene, which codes the antifreeze protein derived from the polar yeast, for a yeast expression system, and for expressing same using the yeast expression system.
    Type: Grant
    Filed: May 17, 2011
    Date of Patent: April 21, 2015
    Assignee: Korea Ocean Research and Development Institute
    Inventors: Hakjun Kim, Sungho Kang, Junhyuck Lee, Sunggu Lee, Sejong Han, Jongchan Park, Kyoungsun Park
  • Publication number: 20150104468
    Abstract: The present disclosure provides methods of site-specific labeling of antibodies, using proteins having 4?-phosphopantetheinyl transferase activity that catalyze post-translational modification of peptide sequences (“peptide tags”) incorporated into one or more specific sites of an antibody of interest. Enzymatic labeling enables quantitative and irreversible covalent modification of a specific serine residue within the peptide tags incorporated into the antibody, and thus creates desirable antibody conjugates.
    Type: Application
    Filed: May 31, 2013
    Publication date: April 16, 2015
    Applicant: IRM LLC
    Inventors: Bernhard Hubert Geierstanger, Jan Grunewald, Badry Bursulaya
  • Publication number: 20150105322
    Abstract: Methods for the expression and purification of non-N-glycosylated human Annexin A2 in yeast, e.g., in Pichia pastoris, purified Annexin A2 produced by those methods, and methods of using the Annexin A2.
    Type: Application
    Filed: October 11, 2012
    Publication date: April 16, 2015
    Inventor: Zhirui Wang
  • Publication number: 20150104458
    Abstract: A polypeptide containing an amino acid sequence having at least 60% identity to the amino acid sequence SEQ ID No. 1 or containing at least one amino acid fragment of at least 6 consecutive amino acid residues of the amino acid sequence SEQ ID No. 1 or having immunological cross-reactivity to the amino acid sequence SEQ ID No. 1 or fragments thereof, wherein the amino acid sequence SEQ ID No. 1 codes for an allergen and the polypeptide comprises at least one T cell epitope recognized by a T cell receptor specific for a molecule having the amino acid sequence SEQ ID No. 1.
    Type: Application
    Filed: August 26, 2014
    Publication date: April 16, 2015
    Applicant: Biomay AG
    Inventors: Rudolf VALENTA, Margit Weghofer, Susanne Vrtala, Friedrich Horak, Peter Valent, Stefan Florian
  • Publication number: 20150105315
    Abstract: The present invention relates to polypeptide fragments comprising an amino-terminal fragment of the PA subunit of a viral RNA-dependent RNA polymerase or variants thereof possessing endonuclease activity, wherein said PA subunit is from a virus belonging to the Orthomyxoviridae family. This invention also relates to (i) crystals of the polypeptide fragments which are suitable for structure determination of said polypeptide fragments using X-ray crystallography and (ii) computational methods using the structural coordinates of said polypeptide to screen for and design compounds that modulate, preferably inhibit the endonucleolytically active site within the polypeptide fragment. In addition, this invention relates to methods identifying compounds that bind to the PA polypeptide fragments possessing endonuclease activity and preferably inhibit said endonucleolytic activity, preferably in a high throughput setting.
    Type: Application
    Filed: October 21, 2014
    Publication date: April 16, 2015
    Applicants: EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL), UNIVERSITY JOSEPH FOURIER FILIALE, Centre National de la Recherche Scientifique - Direction de la Politique Industrielle
    Inventors: Denis Bouvier, Thibaut Crepin, Rob Ruigrok, Alexander Dias, Stephen Cusack
  • Publication number: 20150099278
    Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
    Type: Application
    Filed: December 19, 2014
    Publication date: April 9, 2015
    Inventors: Brenda L. Stevens, Alison Witte, Mark W. Rixon, Josephine M. Cardarelli, Thomas D. Kempe, Scott R. Presnell, Mohan Srinivasan, Susan C. Wong, Guodong Chen, Hui Wei, Stanley R. Krystek, Lumelle A. Schneeweis, Paul O. Sheppard, Indrani Chakraborty
  • Publication number: 20150099705
    Abstract: The present invention relates to Protoxin-II variants, polynucleotides encoding them, and methods of making and using the foregoing.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Inventors: Mack FLINSPACH, Alan Wickenden, Ross Fellows, Robert Neff, Yi Liu, Rebecca Hagan, Qinghao Xu
  • Publication number: 20150099282
    Abstract: The present invention relates to a polypeptide comprising the amino acid sequence of the Bacillus subtilis alanine dehydrogenase or a variant thereof, where Leu197 or an amino acid which is located at a homologous position in the amino acid sequence is exchanged for an amino acid with a positively charged side chain, to a nucleic acid molecule encoding such a polypeptide, and to a process for the production of alanine or a compound generated with consumption of alanine, comprising the step of reacting pyruvate with ammonium and NADPH to give alanine by bringing the pyruvate into contact with the polypeptide according to the invention or with the cell according to the invention.
    Type: Application
    Filed: April 16, 2013
    Publication date: April 9, 2015
    Applicant: EVONIK INDUSTRIES AG
    Inventors: Thomas Haas, Jan Christoph Pfeffer, Arne Skerra, Alexandra Lerchner, Alexander Jarasch
  • Publication number: 20150099861
    Abstract: The present invention relates to humanized monoclonal antibodies comprising the CDRs of murine antibody BMA031, which bind to the apTCR.CD3 complex and possess improved biological properties.
    Type: Application
    Filed: September 12, 2012
    Publication date: April 9, 2015
    Applicant: GENZYME CORPORATION
    Inventors: Daniel Snell, Andreas Menrad, Gina Lacorcia, Srinivas Shankara, Huawei Qiu, Clark Pan, Benjamin Kebble
  • Publication number: 20150098956
    Abstract: Recombinant polypeptides comprising a DR?1 domain, an antigenic peptide, and a linker sequence are disclosed. The linker sequence comprises a first glycine-serine spacer, a thrombin cleavage site and a second glycine-serine spacer. Further disclosed are pharmaceutical compositions comprising the recombinant polypeptides, methods of treating inflammatory disease using said pharmaceutical compositions, and expression constructs comprising nucleic acids that encode the recombinant polypeptides.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Inventors: Arthur A. Vandenbark, Roberto Meza-Romero, Gil Benedek, Gregory G. Burrows
  • Publication number: 20150099276
    Abstract: The present invention relates to the use of nucleic acid molecules coding for a bacterial xylose isomerase (XI), preferably coming from Clostridium phytofermentans, for reaction/metabolization, particularly fermentation, of recombinant microorganisms of biomaterial containing xylose, and particularly for the production of bioalcohols, particularly bioethanol, by means of xylose fermenting yeasts. The present invention further relates to cells, particularly eukaryotic cells, which are transformed utilizing a nucleic acid expression construct which codes for a xylose isomerase, wherein the expression of the nucleic acid expression construct imparts to the cells the capability to directly isomerize xylose into xylulose. Said cells are preferably utilized for reaction/metabolization, particularly fermentation, of biomaterial containing xylose, and particularly for the production of bioalcohols, particularly bioethanol.
    Type: Application
    Filed: December 16, 2014
    Publication date: April 9, 2015
    Inventors: Dawid BRAT, Eckhard BOLES, Marco KELLER, Beate ROTHER
  • Publication number: 20150093797
    Abstract: Provided herein are compositions and methods for the heterologous production of acetyl-CoA-derived isoprenoids in a host cell. In some embodiments, the host cell is genetically modified to comprise a heterologous nucleotide sequence encoding an acetaldehyde dehydrogenase, acetylating (ADA, E.C. 1.2.1.10) and an MEV pathway comprising an NADH-using HMG-CoA reductase. In some embodiments, the host cell is genetically modified to comprise a heterologous nucleotide sequence encoding an ADA and an MEV pathway comprising an acetoacetyl-CoA synthase. In some embodiments, the genetically modified host cell further comprises one or more heterologous nucleotide sequences encoding a phosphoketolase and a phosphotransacetylase. In some embodiments, the genetically modified host cell further comprises a functional disruption of the native PDH-bypass. The compositions and methods described herein provide an energy-efficient yet redox balanced route for the heterologous production of acetyl-CoA-derived isoprenoids.
    Type: Application
    Filed: September 2, 2014
    Publication date: April 2, 2015
    Applicant: AMYRIS, INC.
    Inventors: Timothy Stevens GARDNER, Kristy Michelle HAWKINS, Adam Leon MEADOWS, Annie Ening TSONG, Yoseph TSEGAYE
  • Publication number: 20150094450
    Abstract: The present invention relates to an repebody capable of binding specifically to interleukin-6 (IL-6) to inhibit the biological activity of IL-6, a polynucleotide encoding the repebody, a vector comprising the polynucleotide, a recombinant microorganism having introduced therein the polynucleotide or the vector, a method of producing the repebody using the recombinant microorganism, a composition for preventing or treating cancer, which comprises the repebody, and a method for preventing or treating cancer, which comprises administering the composition for preventing or treating cancer, which comprises the repebody. The repebody of the present invention significantly reduces the activity of STAT3 and the concentration of interleukin-6, and thus can be widely used as an agent for preventing or treating IL-6-related diseases.
    Type: Application
    Filed: February 27, 2013
    Publication date: April 2, 2015
    Applicants: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY, THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC), KOREA BASIC SCIENCE INSTITUTE
    Inventors: Hak-Sung Kim, Joong-Jae Lee, Jung Min Choi, Eun-Kyeong Jo, Chul-Su Yang, Hae-Kap Cheong, Hyun Jung Kim
  • Publication number: 20150093795
    Abstract: The present invention relates tocutinasevariants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Application
    Filed: April 30, 2013
    Publication date: April 2, 2015
    Inventors: Aditya Basu, Naik Sangeeta, Santhosh Mepadam Vasu, Paul Pritish, Rakhi Saikia, Allan Svendsen
  • Publication number: 20150093790
    Abstract: The disclosure provides thermostable enzymes isolated from Caldicellulosiruptor bescii and fragments thereof useful for the degradation of cellulose and/or hemicellulose, including thermostable cellulases and hemicellulases. The disclosure further provides nucleic acids encoding the thermostable enzymes of the disclosure. The disclosure also provides methods for the conversion of cellulose and hemicellulose into fermentable sugars using thermostable enzymes of the disclosure. The disclosure also provides enzyme cocktails containing multiple enzymes disclosed herein. The enzymes can be used to release sugars present in cellulose or hemicellulose for subsequent fermentation to produce value-added products.
    Type: Application
    Filed: December 20, 2011
    Publication date: April 2, 2015
    Applicant: The Board pf Trustees of the University of Illinois
    Inventors: Yejun Han, Xiaoyun Su, Dylan Dodd, Roderick I. Mackie, Issac K.O. Cann
  • Publication number: 20150093781
    Abstract: The invention relates to an isolated, genetically modified, living non-mammal organism, having increased HMG-CoA-reductase activity compared to the wild type, and having reduced C24-methyltransferase and/or delta22-desaturase activity compared to the wild type. The invention is characterized in that the organism has increased dehydrocholesterol-delta70-reductase activity compared to the wild type. The invention further relates to different uses of such an organism, to a test kit comprising such an organism, and to a membrane extract of such an organism.
    Type: Application
    Filed: August 13, 2014
    Publication date: April 2, 2015
    Inventors: Michael Schilling, Christine Lang, Andreas Raab
  • Publication number: 20150093792
    Abstract: The present invention relates to isolated polypeptides having glucoamylase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Application
    Filed: November 24, 2014
    Publication date: April 2, 2015
    Inventors: Sara Landvik, Marc Dominique Morant, Keiichi Ayabe, Guillermo Coward-Kelly
  • Patent number: 8993743
    Abstract: The present invention relates to a nucleic acid molecule encoding a chimeric protein having the biochemical activity of a surface active protein, wherein said chimeric protein comprises: (a) an N-terminal portion of a first surface active protein, wherein the N-terminal portion is devoid of between 0 and 10 of the most N-terminal amino acids of the mature first surface active protein; and, C-terminally thereof, (b) a C-terminal portion of a second surface active protein, wherein the C-terminal portion is devoid of between 0 and 10 of the most C-terminal amino acids of the mature second surface active protein. The present invention further relates to a vector, a non-human host and a method for the production of a chimeric protein having the biochemical activity of a surface active protein. In addition, the present invention relates to a chimeric protein encoded by the nucleic acid molecule of the invention and a composition comprising the chimeric protein.
    Type: Grant
    Filed: February 18, 2011
    Date of Patent: March 31, 2015
    Assignee: B.R.A.I.N. Biotechnology Research and Information Network AG
    Inventors: Guido Meurer, Esther Gabor, Anke Bachert, Jürgen Eck
  • Publication number: 20150086552
    Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
    Type: Application
    Filed: May 21, 2013
    Publication date: March 26, 2015
    Inventors: Brenda L. Stevens, Alison Witte, Mark W. Rixon, Josephine M. Cardarelli, Thomas D. Kempe, Scott R. Presnell, Mohan Srinivasan, Susan C. Wong, Guodong Chen, Hui Wei, Stanley R. Krystek, Lumelle A. Schneeweis, Paul O. Sheppard, Indrani Chakraborty, Milan Gao, Steven Sheriff, Noah Ditto, Nels B. Hamacher
  • Publication number: 20150087028
    Abstract: The invention relates to recombinant expression of variant forms of M. thermophila CBH1a and homologs thereof, having improved thermoactivity, specific activity, and other desirable properties. Also provided are methods for producing ethanol and other valuable organic compounds by combining cellobiohydrolase variants with cellulosic materials.
    Type: Application
    Filed: March 12, 2013
    Publication date: March 26, 2015
    Inventors: Behnaz Behrouzian, Xinkai Xie, Kui Chan, Xiyun Zhang, Vesna Mitchell, Douglas A. Hattendorf